The Long-Term Effects of Cellular Telephone-Delivered Telephone Intervention Problem Solving (TIPS) for Schizophrenia Spectrum Disorders (SSDs): Rationale and Design

2017 ◽  
Vol 11 (3) ◽  
pp. 164-171
Author(s):  
Lora H. Beebe ◽  
Kathlene Smith ◽  
Chad Phillips ◽  
Dawn Velligan ◽  
Abbas Tavakoli
2019 ◽  
Vol 207 (12) ◽  
pp. 1012-1018 ◽  
Author(s):  
Vaios Peritogiannis ◽  
Aikaterini Grammeniati ◽  
Afroditi Gogou ◽  
Panagiota Gioti ◽  
Venetsanos Mavreas

2015 ◽  
Vol 30 (8) ◽  
pp. 1002-1010 ◽  
Author(s):  
A.B. Shmukler ◽  
I.Y. Gurovich ◽  
M. Agius ◽  
Y. Zaytseva

AbstractBackgroundCognitive disturbances are widely pronounced in schizophrenia and schizophrenia spectrum disorders. Whilst cognitive deficits are well established in the prodromal phase and are known to deteriorate at the onset of schizophrenia, there is a certain discrepancy of findings regarding the cognitive alterations over the course of the illness.MethodsWe bring together the results of the longitudinal studies identified through PubMed which have covered more than 3 years follow-up and to reflect on the potential factors, such as sample characteristics and stage of the illness which may contribute to the various trajectories of cognitive changes.ResultsA summary of recent findings comprising the changes of the cognitive functioning in schizophrenia patients along the longitudinal course of the illness is provided. The potential approaches for addressing cognition in the course of schizophrenia are discussed.ConclusionsGiven the existing controversies on the course of cognitive changes in schizophrenia, differentiated approaches specifically focusing on the peculiarities of the clinical features and changes in specific cognitive domains could shed light on the trajectories of cognitive deficits in schizophrenia and spectrum disorders.


2020 ◽  
Vol 8 (2) ◽  
Author(s):  
Pasquale Caponnetto ◽  
Riccardo Polosa

This review focuses on smoking cessation treatments for people with schizophrenia spectrum disorders. It concludes with comments on the significance of the research and why it constitutes an original contribution. We searched PubMed (National Library of Medicine), and PsycINFO (Ovid) (2006-2020) for studies on schizophrenic disorder (schizophrenia or psychotic or psychosis or severe mental illness) and smoking cessation treatment (smoking cessation treatment or varenicline or tobacco cessation or reduction or bupropion or NRT or behavioral treatment or e-cigarette). Studies found evidence suggesting that pharmacotherapy combined with behavioural therapy for smoking cessation is effective amongst smokers with schizophrenia spectrum disorders, although more long-term research is required. This review summarised and critically reviewed also studies on vaping as a smoking cessation strategy for smokers with schizophrenia spectrum disorders and evidence suggests that they may effective as smoking cessation tool and may be less harmful alternatives to combustible cigarette smoking. Consequently, e-cigarettes could be considered as an applicable instrument for Tobacco Harm Reduction (THR) and smoking cessation. Overall, there are very few studies of e-cigarettes for smoking cessation in patients with schizophrenia and these studies are very small. They have promising results, but more research is needed.


2014 ◽  
Vol 24 (5) ◽  
pp. 517-524 ◽  
Author(s):  
Itziar Flamarique ◽  
Inmaculada Baeza ◽  
Elena de la Serna ◽  
Alexandre Pons ◽  
Miguel Bernardo ◽  
...  

2018 ◽  
Vol 49 (13) ◽  
pp. 2206-2214 ◽  
Author(s):  
Christy LM Hui ◽  
William G Honer ◽  
Edwin HM Lee ◽  
WC Chang ◽  
Sherry KW Chan ◽  
...  

AbstractBackgroundAlthough relapse in psychosis is common, a small proportion of patients will not relapse in the long term. We examined the proportion and predictors of patients who never relapsed in the 10 years following complete resolution of positive symptoms from their first psychotic episode.MethodPatients who previously enrolled in a 12-month randomized controlled trial on medication discontinuation and relapse following first-episode psychosis (FEP) were followed up after 10 years. Relapse of positive symptoms was operationalized as a change from a Clinical Global Impression scale positive score of <3 for at least 3 consecutive months to a score of ⩾3 (mild or more severe). Baseline predictors included basic demographics, premorbid functioning, symptoms, functioning, and neurocognitive functioning.ResultsOut of 178 first-episode patients, 37 (21%) never relapsed during the 10-year period. Univariate predictors (p ⩽ 0.1) of patients who never relapsed included a duration of untreated psychosis (DUP) ⩽30 days, diagnosed with non-schizophrenia spectrum disorders, having less severe negative symptoms, and performing better in logical memory immediate recall and verbal fluency tests. A multivariate logistic regression analysis further suggested that the absence of any relapsing episodes was significantly related to better short-term verbal memory, shorter DUP, and non-schizophrenia spectrum disorders.ConclusionsTreatment delay and neurocognitive function are potentially modifiable predictors of good long-term prognosis in FEP. These predictors are informative as they can be incorporated into an optimum risk prediction model in the future, which would help with clinical decision making regarding maintenance treatment in FEP.


Sign in / Sign up

Export Citation Format

Share Document